arrow
M

Monika Joshi

pennsylvania commonwealth system of higher education (pcshe)
H指数:27
被引数:5,108

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study

癌症转移对新型冠状病毒肺炎结局的影响: 基于新型冠状病毒肺炎和癌症协会注册的回顾性队列研究

CANCER
IF5.1
2024-02-200
PRE
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

乳腺癌和新型冠状病毒肺炎患者的临床特征,种族不平等和结局: 新型冠状病毒肺炎和癌症联盟 (CCC19) 队列研究

2023-10-172
OA
Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2023-04-017
OAAI
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

癌症患者接受两剂和三剂新型冠状病毒肺炎mRNA疫苗后的突破性SARS-CoV-2感染: 来自新型冠状病毒肺炎和癌症协会的回顾性观察研究

2023-03-0124
OAAI
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
2023-02-2310
OAAI
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
2022-11-0220
OAAI
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
2021-10-254
OA
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

一线免疫检查点抑制剂治疗晚期尿路上皮癌患者的新预后模型

2021-06-0143
OA
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
2021-02-0823
OAAI